trientine has been researched along with Pregnancy in 21 studies
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.
2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seven patients with Wilson's disease, treated with trientine, have been followed during 11 pregnancies." | 5.27 | The management of pregnancy in Wilson's disease treated with trientine. ( Walshe, JM, 1986) |
| "Because the manifestations of Wilson's disease are so protean, and the disease masquerades so well as something else, recognition of the possibility of Wilson's disease is a major problem, leading to serious underdiagnosis of the disease." | 2.39 | Practical recommendations and new therapies for Wilson's disease. ( Brewer, GJ, 1995) |
| "Patients with Wilson's disease contemplating pregnancy should have their hepatic function and copper status assessed." | 1.29 | Wilson's disease in pregnancy. ( Goulding, P; Hawthorne, B; Maresh, M; Nunns, D, 1995) |
| "Seven patients with Wilson's disease, treated with trientine, have been followed during 11 pregnancies." | 1.27 | The management of pregnancy in Wilson's disease treated with trientine. ( Walshe, JM, 1986) |
| "Twenty patients with Wilson's disease in whom severe penicillamine intolerance developed have been managed with the orally active chelating agent trientine dihydrochloride (trien)." | 1.26 | Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. ( Walshe, JM, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (52.38) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pfeiffenberger, J | 1 |
| Beinhardt, S | 1 |
| Gotthardt, DN | 1 |
| Haag, N | 1 |
| Freissmuth, C | 1 |
| Reuner, U | 1 |
| Gauss, A | 1 |
| Stremmel, W | 1 |
| Schilsky, ML | 2 |
| Ferenci, P | 1 |
| Weiss, KH | 1 |
| Dathe, K | 1 |
| Beck, E | 1 |
| Schaefer, C | 1 |
| Pérez-Aguilar, F | 1 |
| Walshe, JM | 2 |
| Keen, CL | 6 |
| Cohen, NL | 4 |
| Lönnerdal, B | 5 |
| Hurley, LS | 5 |
| Watson, RG | 1 |
| Nunns, D | 1 |
| Hawthorne, B | 1 |
| Goulding, P | 1 |
| Maresh, M | 1 |
| Devesa, R | 1 |
| Alvarez, A | 1 |
| de las Heras, G | 1 |
| Ramón de Miguel, J | 1 |
| Tanaka, H | 2 |
| Inomata, K | 1 |
| Arima, M | 1 |
| Brewer, GJ | 3 |
| Sternlieb, I | 1 |
| Yamanouchi, M | 1 |
| Imai, S | 1 |
| Hayashi, Y | 1 |
| Yuzbasiyan-Gurkan, V | 2 |
| Dubick, MA | 1 |
| Rucker, RB | 1 |
| Young, AB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease[NCT01472874] | 8 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | g/dL (Mean) |
|---|---|
| Once a Day Trientine | 0.52 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | g/dL (Mean) |
|---|---|
| Once a Day Trientine | 0.54 |
Alanine transaminase (NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | U/L (Mean) |
|---|---|
| Once a Day Trientine | 50.89 |
Alanine transaminase (NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | U/L (Mean) |
|---|---|
| Once a Day Trientine | 41.38 |
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | mcg/24h (Mean) |
|---|---|
| Once a Day Trientine | 0.52 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | mcg/24h (Mean) |
|---|---|
| Once a Day Trientine | 0.54 |
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 313.4 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 287.9 |
The International Normalized Ratio (INR) is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy (NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | international normalized ratio (Mean) |
|---|---|
| Once a Day Trientine | 1.05 |
The International Normalized Ratio (INR) is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy (NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | international normalized ratio (Mean) |
|---|---|
| Once a Day Trientine | 0.99 |
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 2214 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 1959 |
6 reviews available for trientine and Pregnancy
| Article | Year |
|---|---|
[Wilson's disease: physiopathological, clinical and therapeutic considerations].
Topics: Adenosine Triphosphatases; Adolescent; Adult; Basal Ganglia Diseases; Brain; Cation Transport Protei | 2003 |
Practical recommendations and new therapies for Wilson's disease.
Topics: Chelating Agents; Copper; Female; Hepatolenticular Degeneration; Humans; Liver; Metallothionein; Mol | 1995 |
Wilson's disease and pregnancy.
Topics: Chelating Agents; Female; Hepatolenticular Degeneration; Humans; Penicillamine; Pregnancy; Pregnancy | 2000 |
Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation?
Topics: Adenosine Triphosphatases; Chelating Agents; Drug Therapy, Combination; Female; Hepatolenticular Deg | 2001 |
Wilson's disease: an update, with emphasis on new approaches to treatment.
Topics: Copper; Female; Hepatolenticular Degeneration; Humans; Molybdenum; Penicillamine; Pregnancy; Trienti | 1989 |
Treatment of Wilson's disease.
Topics: Copper; Ethylenediamines; Female; Hepatolenticular Degeneration; Humans; Penicillamine; Pregnancy; T | 1987 |
15 other studies available for trientine and Pregnancy
| Article | Year |
|---|---|
Pregnancy in Wilson's disease: Management and outcome.
Topics: Adolescent; Adult; Female; Hepatolenticular Degeneration; Humans; Liver; Liver Function Tests; Pregn | 2018 |
Pregnancy outcome after chelation therapy in Wilson disease. Evaluation of the German Embryotox Database.
Topics: Adult; Chelating Agents; Chelation Therapy; Copper; Databases, Factual; Female; Germany; Hepatolenti | 2016 |
Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
Topics: Adolescent; Adult; Brain; Ethylenediamines; Female; Hepatolenticular Degeneration; Humans; Male; Pen | 1982 |
Low tissue copper and teratogenesis in trientine-treated rats.
Topics: Abnormalities, Drug-Induced; Animals; Copper; Depression, Chemical; Ethylenediamines; Female; Humans | 1982 |
Drug-induced copper deficiency: a model for copper deficiency teratogenicity.
Topics: Abnormalities, Drug-Induced; Animals; Copper; Female; Humans; Penicillamine; Pregnancy; Teratogens; | 1983 |
The effect of copper supplementation on the teratogenic effects of triethylenetetramine in rats.
Topics: Animals; Body Weight; Copper; Diet; Drug Interactions; Ethylenediamines; Female; Fetal Resorption; F | 1983 |
Teratogenesis and low copper status resulting from triethylenetetramine in rats.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Copper; Dose-Response Relationship, Drug; Ethylen | 1983 |
Wilson's disease in one identical twin and treatment by triethylene tetramine 2HCl in another case.
Topics: Adolescent; Adult; Diseases in Twins; Ethylenediamines; Female; Hepatolenticular Degeneration; Human | 1983 |
Molecular localization of copper and zinc in rat fetal liver in dietary and drug-induced copper deficiency.
Topics: Abnormalities, Drug-Induced; Animals; Chromatography, Gel; Copper; Ethylenediamines; Female; Liver; | 1984 |
Wilson's disease in pregnancy.
Topics: Adolescent; Copper; Female; Hepatolenticular Degeneration; Humans; Liver; Male; Penicillamine; Pregn | 1995 |
Wilson's disease treated with trientine during pregnancy.
Topics: Adult; Ceruloplasmin; Copper; Female; Fetal Blood; Hepatolenticular Degeneration; Humans; Infant, Ne | 1995 |
Teratogenic effects of triethylene tetramine dihydrochloride on the mouse brain.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Female; Litter Size; Mice; Mice, Inbred C3H; Pregn | 1993 |
Low copper and brain abnormalities in fetus from triethylene tetramine dihydrochloride-treated pregnant mouse.
Topics: Animals; Body Weight; Brain; Copper; Female; Gestational Age; Liver; Maternal-Fetal Exchange; Mice; | 1992 |
Elastin metabolism during perinatal lung development in the copper-deficient rat.
Topics: Animals; Animals, Newborn; Collagen; Copper; Elastin; Female; Liver; Lung; Penicillamine; Pregnancy; | 1985 |
The management of pregnancy in Wilson's disease treated with trientine.
Topics: Adult; Ceruloplasmin; Copper; Ethylenediamines; Female; Hepatolenticular Degeneration; Humans; Pregn | 1986 |